tbuckley/cabot-search huggingface dataset:
Genome-Wide Analysis of BRD4-Targets Reveals the Therapeutic Relevance of Simultaneous Targeting of BCR Pathway and IKZF-MYC Axis in Mantle Cell Lymphoma
Authors: Junya Kuroda, Taku Tsukamoto, Shingo Nakahata, Kazuhiro Morishita, Ryuichi Sato, Akinori Kanai, Toshiya Inaba, Masakazu Nakano, Kei Tashiro, Masafumi Taniwaki
Journal: Blood (2018)
Abstract 14219: Enhancing Cardiac Beta-Hydroxybutyrate Consumption Halts the Progression From Compensated to Decompensated Heart Failure in Dogs With Tachypacing-Induced Dilated Cardiomyopathy
Authors: Clara Kurishima, Jeffery C Powers, Mitsuru Seki, Pavithra Kavitha, Florence Tsipenyuk, Keely Cunningham, Heramba V Gopi, Timothy Matsuura, Daniel P Kelly, Fabio A Recchia
Journal: Circulation (2018)

Introduction: Recent Evidence indicates that circulating ketone bodies serve as an alternative myocardial substrate in heart failure (HF). Hypothesis: We tested the hypothesis that enhancing ketone...
Comparative Effectiveness and Maintenance of Diabetes Self-Management Education Interventions for Marshallese Patients With Type 2 Diabetes: A Randomized Controlled Trial
Authors: Pearl A. McElfish, Christopher R. Long, Peter O. Kohler, Karen H.K. Yeary, Zoran Bursac, Marie-Rachelle Narcisse, Holly C. Felix, Brett Rowland, Jonell S. Hudson, Peter A. Goulden
Journal: Diabetes Care (2019)

OBJECTIVE Marshallese adults experience high rates of type 2 diabetes. Previous diabetes self-management education (DSME) interventions among Marshallese were unsuccessful. This study compared the extent to which two DSME interventions improved glycemic control, measured on the basis of change in glycated hemoglobin (HbA1c). RESEARCH DESIGN AND METHODS A two-arm randomized controlled trial compared a standard-model DSME (standard DSME) with a culturally adapted family-model DSME (adapted DSME). Marshallese adults with type 2 diabetes (n = 221) received either standard DSME in a community setting (n = 111) or adapted DSME in a home setting (n = 110). Outcome measures were assessed at baseline, immediately after the intervention, and at 6 and 12 months after the intervention and were examined with adjusted linear mixed-effects regression models. RESULTS Participants in the adapted DSME arm showed significantly greater declines in mean HbA1c immediately (−0.61% [95% CI −1.19, −0.03]; P = 0.038) and 12 months (−0.77% [95% CI −1.38, −0.17]; P = 0.013) after the intervention than those in the standard DSME arm. Within the adapted DSME arm, participants had significant reductions in mean HbA1c from baseline to immediately after the intervention (−1.18% [95% CI −1.55, −0.81]), to 6 months (−0.67% [95% CI −1.06, −0.28]), and to 12 months (−0.87% [95% CI −1.28, −0.46]) (P &amp;lt; 0.001 for all). Participants in the standard DSME arm had significant reductions in mean HbA1c from baseline to immediately after the intervention (−0.55% [95% CI −0.93, −0.17]; P = 0.005). CONCLUSIONS Participants receiving the adapted DSME showed significantly greater reductions in mean HbA1c immediately after and 12 months after the intervention than the reductions among those receiving standard DSME. This study adds to the body of research that shows the potential effectiveness of culturally adapted DSME that includes participants’ family members.
Designing Melittin‐Graphene Hybrid Complexes for Enhanced Antibacterial Activity
Authors: Xuemei Lu, Jiaojiao Liu, Lu Gou, Jingliang Li, Bing Yuan, Kai Yang, Yuqiang Ma
Journal: Advanced Healthcare Materials (2019)

Abstract Antimicrobial peptides (AMPs) promise a fundamental solution to the devastating threat of drug‐resistant bacteria. However, drawbacks of AMPs (e.g., poor cell membrane penetration efficiency) seriously block their clinical use. In this work, rational design of a hybrid complex of melittin (as a representative AMP) and graphene or graphene oxide (Gra or GO) nanosheets for enhanced antibacterial ability is achieved, via combining in‐silico prediction and in‐tube test. In comparison to pristine melittin, the specifically designed AMP‐Gra (/GO) complex exhibits remarkable efficiency in transmembrane perforation with an over tenfold decrease in the threshold working concentration of peptide; moreover, it has an up to 20‐fold enhancement in antibacterial activity against both Gram‐negative and Gram‐positive bacteria. Such improvement is ascribed to the synergetic insertion of nanosheets and melittin due to similarity in antibacterial mechanism between them and is further regulated by the structural factors of the complex, including the intersheet spacing and surface functionalization of the Gra/GO sheets, etc. These results provide practical guidelines to engineer AMPs with nanotechnology for improved antimicrobial performances, especially based on targeted functionalization of the Gra/GO nanosheets.
Pore-forming bioinks to enable spatio-temporally defined gene delivery in bioprinted tissues
Authors: T. Gonzalez-Fernandez, S. Rathan, C. Hobbs, P. Pitacco, F.E. Freeman, G.M. Cunniffe, N.J. Dunne, H.O. McCarthy, V. Nicolosi, F.J. O'Brien, D.J. Kelly
Journal: Journal of Controlled Release (2019)
Abstract P240: Sugar-Sweetened Beverage Intake and Cardiovascular Disease Risk in the California Teachers Study
Authors: Lorena S Pacheco, James V Lacey, Maria E Martinez, Hector Lemus, Cheryl A Anderson
Journal: Circulation (2019)

Introduction: Previous observational studies have shown a positive association between sugar-sweetened beverage (SSB) consumption and cardiovascular disease (CVD) risk, but many have been relatively short-term. Objective: To determine the association of SSB consumption over a 20-year period and incident CVD in a large prospective cohort of middle-aged women. Methods: Data are from the California Teachers Study, a US based longitudinal cohort comprised of 133,477 female teachers and administrators who were active or recently retired members of the California State Teachers Retirement System in 1995. After excluding those with a history of CVD and type 2 diabetes mellitus at baseline, our analytic sample was 107,905. SSB consumption constituted regular soft drinks, sweetened bottled waters and teas, and fruit drinks (other than fruit juice) and was derived from a self-administered Block95 food frequency questionnaire. SSB consumption was divided into four categories: Rare or never, &gt;rare/never to &lt;1 serving per week, ≥1 serving per week to &lt;1 serving per day, and ≥1 serving per day. CVD endpoints were based on annual linkage with statewide hospitalization records, defined as first occurrence of myocardial infarction, coronary artery bypass grafting (CABG) or stroke following the International Statistical Classification of Diseases 9 th and 10 th Revision coding system. Cox proportional hazards models were used to assess the association between SSB consumption and incident CVD, after adjusting for potential confounders and mediators. Results: Of a total of 8,946 CVD incident cases over 20 years, the majority were strokes (5,728). In an age-adjusted model, we observed increased hazard ratios (HR) for CVD (HR 1.24 [95% CI 1.11, 1.38]), CABG (HR 1.39 [95% CI 1.13, 1.71]), and stroke (HR 1.21 [95% CI 1.05, 1.39]) events in women who consumed ≥1 serving/day vs those who rarely/never consumed SSBs. Our fully adjusted model included age, smoking, alcohol intake, physical activity, multivitamin and aspirin use, menopausal status, hormone replacement therapy, oral contraceptive use, history of hypertension, body mass index, fruit and vegetable intake, and total energy intake. This model slightly attenuated the hazard for CVD (HR 1.20 [95% CI 1.07, 1.35]), CABG (HR 1.25 [95% CI 1.00, 1.06]), and stroke (HR 1.18 [1.01, 1.37]) in women who consumed ≥1 serving/day in comparison to women that rarely/never consumed SSBs. Conclusions: If this finding is replicated, SSB consumption might be a modifiable dietary target to reduce risk of CVD among women.
Recalibration of genomic risk prediction models in prostate cancer to improve individual-level predictions.
Authors: Elai Davicioni, Voleak Choeurng, Bin Luo, Kasra Yousefi, Heesun Shin, Zaid Haddad, Ashley Ross, Edward M. Schaeffer, Robert Benjamin Den, Adam Dicker, R. Jeffrey Karnes, Darby J. S. Thompson
Journal: Journal of Clinical Oncology (2015)

e16122 Background: Despite the obvious clinical importance, a test's calibration is rarely described in clinical validation studies. Full descriptions of the development of qualitative risk categories for a test's continuous score can be just as uncommon. This investigation demonstrates the process of recalibration and construction of clinically meaningful cut-points for a validated genomic test, Decipher, used for predicting post-surgical metastatic progression. The performance of the recalibrated test is evaluated in an external validation set. Methods: Decipher is recalibrated on a case-cohort set (n = 216) using a flexible proportional-hazards model, capable of accommodating typical departures from the proportionality assumption with performance assessed through a number of metrics; calibration-in-the-large, calibration slope, goodness-of-fit, modified Hosmer-Lemshow. Cut-points of the recalibrated score are developed using a resampling method to optimize the partial likelihood of a Cox model. An independent set of 139 patients is used for validation of the recalibrated scores and the developed cut-points. Results: The described methods are shown to provide acceptable calibration in both the training (p-value = 0.696) and validation sets (p-value = 0.487). Based on the Cox model, the optimized cut-points for Decipher were 0.45 and 0.60 when stratifying patients into three meaningful risk categories (p < 0.001). In the external validation set, patients with a Decipher score of 0.45-0.60 had a 2.7-fold increase in risk while those with scores > 0.60 had a 5.8-fold increase in risk when compared to patients whose Decipher scores were < 0.45. Conclusions: Prognostic genomic tests can be recalibrated on time-to-event data, to make the test's individual-level predictions as accurate as possible and provide a statistical basis for clinically-interpretable cut-points. The methods are also shown to apply to series of prognostic tests regardless of their method of discovery or model.
Undissected Axilla and Axillary Radiotherapy—In Reply
Authors: Monica Morrow, Reshma Jagsi, Steven J. Katz
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): Efficacy results of phase II trial.
Authors: Alexey Tryakin, Mikhail Fedyanin, Urii Sergeev, Anatoly Bulanov, Bahrom Ahmedov, Tatiana Zakharova, Andrey Mitin, Igor Fainstein, Avgust Garin, Sergei Tjulandin
Journal: Journal of Clinical Oncology (2015)

e15566 Background: Three-weekly BEP has been a standard of chemotherapy of advanced NSGCT for last two decades. We performed a phase II study to assess the efficacy and toxicity of two-weekly aBEP regimen in the first line treatment of NSGCT. Here we report efficacy results. Methods: Chemotherapy-naïve NSGCT pts with intermediate or poor prognosis (IGCCCG) received aBEP as follows: cisplatin 20 mg/m2 days 1-5, etoposide 100 mg/m2 days 1-5, bleomycin 30 IU days 1,3,5 with G-CSF support 300 mcg days 6-10. Four cycles of aBEP were administered every 2 weeks. The primary endpoint was 1-year PFS after completion of chemotherapy. The hypotheses being tested was Ho: p0 = pexp (p0= 0.65). Assuming pexp= 0.80 with a two-sided type I error of 0.05, a type II error of 0.2, patient drop-out rate of 10%, 61 pts were required. Results: From 2010 to 2013, 61 pts were treated. Intermediate and poor prognosis according IGCCCG had 36 (59%) and 25 (41%) of pts, respectively. In poor prognostic group mediastinal primary tumor had 7 (18%) pts, non-pulmonary visceral metastases - 12 (48%) pts. There were no toxic deaths. Safety results were reported elsewhere (ASCO 2014, #e15540). Median time of f.-up was 36 (5-58) months. 1-year PFS for all pts was 78%. In pts with intermediate and poor prognosis 3-year PFS was 88% and 48%, respectively. These results were similar with efficacy of 3-weekly BEP in our centre. Conclusions: Two-weekly BEP regimen can be safely administered to NSGCT pts with intermediate and poor prognosis. No clearly benefit in PFS was seen comparing with 3-weekly BEP in both prognostic groups.
Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis
Authors: Tatsuji Mino, Yuta Katayama, Tatsuya Terasaki, Yu Kochi, Fumiaki Jinnouchi, Takeshi Okatani, Ryota Imanaka, Kohei Kyo, Mitsuhiro Itagaki, Shinya Katsutani, Tsuyoshi Muta, Koji Iwato, Hideki Asaoku
Journal: Blood (2018)
Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Authors: Yang Liu, Stefan Klaus Barta
Journal: American Journal of Hematology (2019)

Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it represents a heterogeneous group of diseases with variable outcomes that are differentially characterized by clinical features, cell of origin (COO), molecular features, and most recently, frequently recurring mutations. Diagnosis DLBCL is ideally diagnosed from an excisional biopsy of a suspicious lymph node, which shows sheets of large cells that disrupt the underlying structural integrity of the follicle center and stain positive for pan‐B‐cell antigens, such as CD20 and CD79a. COO is determined by immunohistochemical stains, while molecular features such as double‐hit or triple‐hit disease are determined by fluorescent in situ hybridization analysis. Commercial tests for frequently recurring mutations are currently not routinely used to inform treatment. Risk Stratification Clinical prognostic systems for DLBCL, including the rituximab International Prognostic Index, age‐adjusted IPI, and NCCN‐IPI, use clinical factors for the risk stratification of patients, although this does not affect the treatment approach. Furthermore, DLBCL patients with non‐germinal center B‐cell (GCB)‐like DLBCL (activated B‐cell like and unclassifiable) have a poorer response to up‐front chemoimmunotherapy (CI) compared to patients with GCB‐like DLBCL. Those with c‐MYC‐altered disease alone and in combination with translocations in BCL2 and/or BCL6 (particularly when the MYC translocation partner is immunoglobulin) respond poorly to up‐front CI and salvage autologous stem cell transplant at relapse. Risk‐Adapted Therapy This review will focus on differential treatment of DLBCL up‐front and at the time of relapse by COO and molecular features.
Chlamydophila psittaci (CP) is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal malt lymphoma (OAML): Results of a prospective trial
Authors: A. J. Ferreri, R. Dolcetti, G. P. Dognini, L. Malabarba, N. Vicari, E. Pasini, M. Ponzoni, M. Cangi, L. Pecciarini, A. Giordano Resti, C. Doglioni, S. Rossini, S. Magnino
Journal: Annals of Oncology (2008)
Abstract P242: Association of Obesity With Arterial Stiffness: The Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Jeongok Logan, Hyojung Kang, Soyoun Kim, Daniel Duprez, Younghoon Kwon, David Jacobs, Nketi Forbang, Jennifer M Lobo, Min-Woong Sohn
Journal: Circulation (2019)

Background: Arterial stiffness is recognized as an important subclinical marker of cardiovascular disease (CVD). However, the relationship between obesity and arterial stiffness is unclear. Methods: Applanation tonometry was used to estimate arterial stiffness, defined as high augmentation index (AIx) and low C1 and C2 in participants enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA) at baseline. Analysis of covariance was used to compare AIx, C1, and C2 across categories of body mass index (BMI) (&lt;25, 25-29.9, 30-39.9, &gt; 40 kg/m 2 ) and waist-hip ratio (WHR) (&lt;0.85, 0.85-0.99, ≥1). Age-obesity interaction was tested among obesity groups across age categories (45 - 54, 55 - 64, 65 - 74, and 75 - 84 years old). Results: Among 6,177 participants (mean age 62±10 years, 52% female), there was significant inverse relationship between obesity and arterial stiffness. After adjustments for CVD risk factors, participants with BMI &gt; 40 kg/m 2 had 5.4% lower AIx (mean difference [Δ] = -0.83; 95% CI, -1.12 - -0.54), 13.5% higher C1 (Δ = 1.40; 95% CI, 0.73 - 2.07), and 41.2% higher C2 (Δ = 1.53; 95% CI, 1.19 - 1.88) compared to participants with BMI &lt; 25 kg/m 2 (all p for trend &lt;0.001). Participants with WHR ≥ 1 had 1.7% lower AIx (Δ = -0.26; 95% CI, -0.46 - -0.06), 6.1% higher C1 (Δ = 0.98; 95% CI, 0.53 - 1.43), and 6.1% higher C2 (Δ = 0.28; 95% CI, 0.05 - 0.51) compared to those with WHR &lt;0.85 (all p for trend &lt; 0.05). WHR had a significant interaction with age on AIx and C2, and the inverse relationship between WHR and arterial stiffness was only observed in participants aged &lt; 55 years. Conclusions: Obesity as measured by BMI and WHR was associated with lower arterial stiffness presented as lower AIx and higher C1 and C2. There was a significant age interaction with WHR on AIx and C2, but not with BMI. Differential effects of WHR versus BMI on arterial stiffness in older adults should be further investigated in future studies.
A study of EGFR mutation in nonsmoker NSCLC: Striking disparity between north and south India patients.
Authors: Shyam Aggarwal, Shekhar Patil, Sachin Minhans, Manish Pungliya, Soumitra N
Journal: Journal of Clinical Oncology (2012)

e18041 Background: There is a high incidence of EGFR mutation in non-smokers with adenocarcinoma of lung- 70% the south-east Asia and 15% in Caucasians. There is no study in an Indian population yet. Methods: 55 cases of non smoker advanced adenocarcinoma of lung were enrolled in this study after June, 2008 in a retrospective fashion. 26 patients were enrolled from Sir Ganga Ram Hospital, Delhi in North India and 29 from HCG, Bangalore in South India. Assessment of mutation status was possible in 49 cases. ARMS technique was used to study the EGFR mutation. Results: A total 27 out of 49 cases were positive for EGFR mutation – 7/21 (33%) from North India and 20/28 (65%) from South India. The commonest mutation was del exon 19 (62%), followed by L858R exon 21 (25%), G719X exon 18 (7%) and insertion exon 20 (3%). Patients were treated either with gefitinib or chemotherapy. 8/12 (83%) patients treated with gefitinib upfront responded. Overall survival (OS) was not reached at a follow up of 11 months in EGFR mutation carriers. Only 2/27 patients died. Of the 22 cases with no EGFR mutation, 6 were treated with gefitinib in frontline and the rest with chemotherapy. OS was reached at 10 months in patients with no EGFR mutation. 10/22 of these patients died. Conclusions: The study brings about striking differences in the incidence of EGFR mutation in non-smoker NSCLC cases between North and South India. This could be due to ethnic issues. There is a need to continue to this study in these patient populations.
Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351
Authors: Christine M. McMahon, Nya Nelson, Alex Ganetsky, James K. Mangan, Noelle V. Frey, Alexander E. Perl, Mary Ellen Martin, Shannon R. McCurdy, Alison W. Loren, Elizabeth O. Hexner, Adam Bagg, Jennifer J.D. Morrissette, Selina Luger
Journal: Blood (2018)
The War of All Against All
Authors: Jack Coulehan
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal